

FIG. 2B




FIG. 2C

FIG. 2D




Fig. 3A






Fig. 3B






FIG. 6

TABLE 20" 372207660

**Graph of Linear Regression Analysis
for a Selected Measurement Vector**




FIG. 7




FIG. 8A

A





FIG. 8B

B



C




FIG. 8C

D




FIG. 8D

FIG. 9A




FIG. 9B





FIG. 9C




FIG. 9D

FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E




FIG. 11F




FIG. 12

Patient Clinical Data

Patient	Sex	Infarct Location	Time from MI to EP Study (years)	Drug Therapy	VT Cycle-Length at Onset (ms)
1	M	Ant	3	Amiodarone	328
2	M	Inf-lat	11	Sotalol	368
3	M	Multiple	9	Amiodarone	432
4	M	Ant	15	Amiodarone	272
5	M	Post	5	Amiodarone	251
6	M	Multiple	12	Amiodarone + mex	473
7	M	Inf-lat	5	Amiodarone + mex	197
8	M	Inf	2	Amiodarone	401
9	M	Inf-lat	4	Amiodarone	243
10	F	Inf	1	Amiodarone	287
11	M	Inf	2	Amiodarone	252 (no reentry)
12	M	Ant	14	Sotalol	384
13	M	Ant	1	Amiodarone	249 (no reentry)
14	M	Ant	11	Amiodarone	223 (no reentry)

FIG. 13

